

Bevacizumab

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



Not qualified for an ESMO-MCBS credit



Serious and disabling adverse effects



Other adjustments



Bevacizumab

SCORE

CURATIVE




Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE




Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Thoracic Malignancies  
Therapeutic Indication: First-line, unresectable advanced, metastatic or recurrent NSCLC other than predominantly squamous cell histology  
Experimental Arm: Bevacizumab + Paclitaxel + carboplatin  
Control Arm: Paclitaxel + carboplatin

